Michael O. Alberti, MD, PhD

Instructor, Pathology & Immunology

Education

  • BS, Biochemistry & Molecular Biology: California Lutheran University, Thousand Oaks, CA (2005)
  • PhD, Pathology: University of Alabama at Birmingham, Birmingham, AL (2011)
  • MD: University of Alabama at Birmingham, Birmingham, AL (2013)
  • Residency, Clinical Pathology: University of California Los Angeles Medical Center, Los Angeles, CA (2016)
  • Fellowship, Molecular Genetic Pathology: Washington University School of Medicine (2017)

Board Certifications

  • American Board of Pathology, Clinical Pathology (2016)
  • American Board of Pathology, Molecular Genetic Pathology (2017)

Recognition

  • Barry M. Goldwater Foundation Scholar (2004)
  • Glenn T. Seaborg Science Award, Swedish Council of America (2005)
  • William Boyd Medal for Excellence in Pathology, Alabama Association of Pathologists and UAB Department of Pathology (2013)
  • Paul E. Strandjord Young Investigator Award, Academy of Clinical Laboratory Physicians and Scientists (2015)
  • Career Development Award, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA (2015-2016)
  • Paul Calabresi K12 Career Development Award in Clinical Oncology, WUSM Clinical Research Training Center (2019-2021)
  • Abstract Achievement Award, American Society of Hematology (2019)
  • Outstanding Citizenship Award, WUSM Clinical Research Training Center (2021)
  • EvansMDS Young Investigator Award, Edward P. Evans Foundation (2021-2024)
  • K08 Mentored Clinical Scientist Research Career Development Award, NIH/NHLBI (2021-2026)

Clinical Interests

  • Molecular Pathology
  • Genetics of Myeloid Malignancies (MDS, MPN, AML)

Research Interests

As a physician-scientist I am interested in understanding the genetic and molecular basis of splicing factor gene mutations in clonal hematopoiesis and myeloid malignancies, such as myelodysplastic syndromes (MDS). My work in the laboratory of Dr. Matthew J. Walter has demonstrated that mutations in the U2AF1 splicing factor gene provide an ideal model for these studies as they occur at one of two hotspot codons (S34 and Q157) in separate zinc finger domains, and each of these mutations are associated with different clinical features, outcomes, alternative splicing, and co-occurring gene mutations in MDS patients. Complementary experiments using U2af1(S34F/+) and U2af1(Q157R/+) conditional knock-in mice support these observations and have also revealed differential activation of several key signaling pathways. My long-term goal is to establish an independent research program focused on the following questions: (1) Why are splicing factor mutations highly enriched in clonal myeloid malignancies (e.g., MDS) compared to other types of cancer? (2) What are the individual and shared mechanisms by which different splicing factor mutations induce MDS? (3) What are the dynamics facilitating the acquisition of additional mutations in the context of splicing factor mutant disease?

Publications

Alberti MO, Roth JC, Ismail M, Tsuruta Y, Abraham E, Pereboeva L, Gerson SL, Curiel DT. Derivation of a myeloid cell-binding adenovirus for efficient gene transfer of inflammation. PLoS ONE. 2012; 7(5): e37812. PMCID: PMC3356302. http://dx.doi.org/10.1371/journal.pone.0037812
Alberti MO, Deshane JS, Chaplin DD, Pereboeva L, Curiel DT, Roth JC. A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism. Gene Ther. 2013 Jul; 20(7): 733−41. PMCID: PMC3764611. http://dx.doi.org/10.1038/gt.2012.91
Alberti MO, Fukuchi AM, Kelly KA. Influence of serum separator tubes on mycophenolic acid concentrations determined by HPLC. Ther Drug Monit. 2014 Oct; 36(5): 686−7. PMID: 24718269. http://dx.doi.org/10.1097/FTD.0000000000000066
Roth JC, Alberti MO, Ismail, M, Reese JS, Gerson SL. MGMT enrichment and second gene co-expression in hematopoietic progenitor cells using separate or dual-gene lentiviral vectors. Virus Res. 2015 Jan; 196: 170−80. PMID: 25479595. http://dx.doi.org/10.1016/j.virusres.2014.11.027
Alberti MO, Jones JJ, Miglietta R, Ding H, Bakshi RK, Edmonds, TG, Kappes JC, Ochsenbauer C. Optimized replicating Renilla luciferase reporter HIV-1 utilizing novel IRES elements for native Nef expression and function. AIDS Res Hum Retroviruses. 2015 Dec; 31(12): 1278−96. PMCID: PMC4663642. http://dx.doi.org/10.1089/aid.2015.0074
Alberti MO, Hindler JA, Humphries, RM. Antimicrobial susceptibility of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans. Antimicrob Agents Chemother. 2015 Dec; 60(3): 1411−20. PMCID: PMC4776019. http://dx.doi.org/10.1128/AAC.02645-15
Fernando TR, Contreras JR, Zampini M, Rodríguez-Malavé NI, Alberti MO, Anguiano J, Tran TM, Palanichamy JK, Gajeton J, Ung NM, Aros CJ, Waters EV, Casero D, Basso G, Pigazzi M, Rao DS. The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. Mol Cancer. 2017 Jul; 16(1): 126. PMCID: PMC5517805. http://dx.doi.org/10.1186/s12943-017-0692-x
Alberti MO, Srivatsan SN, Shao J, McNulty SN, Chang GS, Miller CA, Dunlap JB, Yang F, Press RD, Gao Q, Ding L, Heusel JW, Duncavage EJ, Walter MJ. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. Leukemia. 2018 Aug; 32(8): 1874−1878. PMCID: PMC6402595. http://dx.doi.org/10.1038/s41375-018-0193-y
Mullegama SV, Alberti MO, Au C, Li Y, Toy T, Tomasian V, Xian RR. Nucleic acid extraction from human biological samples. In: Biobanking. (Yong WH, Ed.). Methods Mol Biol. 2019; 1897: 359−383. Humana Press, New York, NY. PMID: 30539458. http://dx.doi.org/10.1007/978-1-4939-8935-5_30
Jaiswal AK, Truong H, Tran TM, Lin TL, Casero D, Alberti MO, Rao DS. Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. Sci Reports. 2021 Jun; 11: 13158. PMCID: PMC8222245. http://dx.doi.org/10.1038/s41598-021-92448-w